Assessing Vaccine Herd Protection by Killed Whole-Cell Oral Cholera Vaccines Using Different Study Designs.

cholera clinical trial gis herd effects vaccine

Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2019
Historique:
received: 08 01 2019
accepted: 16 07 2019
entrez: 17 8 2019
pubmed: 17 8 2019
medline: 17 8 2019
Statut: epublish

Résumé

The population level effectiveness of a vaccine may arise as the result of direct protection of vaccinees and vaccine herd protection, which may protect non-vaccinees, vaccinees, or both. Indirect, total, enhanced, and overall vaccine protection are measures of vaccine herd protection. The level of population level effectiveness induced by a vaccine is driven by several factors, including known vaccine-induced protective efficacy, the magnitude, and distribution of vaccine coverage at a point in time and the extent to which different groups mix with one another in the community. Data on vaccine herd protection are valuable in understanding the importance and cost-effectiveness in deploying the e vaccine in public health program. Killed whole-cell (WC) oral cholera vaccines (OCVs) have been evaluated for herd protection in various study settings, leveraging geographic information system (GIS) tools for the analyses. This article provides a brief description of the herd protective effects of killed WC OCVs measured using various study deigns that include (a) individually randomized, controlled clinical trials, (b) cluster randomized clinical trials, (c) observational cohort studies, and (d) observational case-control studies. In all of the study designs, significant herd protection was observed in unvaccinated persons as well as in the community as a whole. The findings of these studies suggest that using killed WC OCV as a public health tool for controlling cholera is impactful and cost-effective.

Identifiants

pubmed: 31417890
doi: 10.3389/fpubh.2019.00211
pmc: PMC6685418
doi:

Types de publication

Journal Article

Langues

eng

Pagination

211

Références

Epidemiol Rev. 1999;21(1):73-88
pubmed: 10520474
Stat Med. 2002 Feb 28;21(4):481-95
pubmed: 11836731
Emerg Infect Dis. 2003 Feb;9(2):204-10
pubmed: 12603991
Int J Health Geogr. 2005 Jun 01;4(1):12
pubmed: 15927082
Lancet. 2005 Jul 2-8;366(9479):44-9
pubmed: 15993232
Epidemiology. 1991 Sep;2(5):331-8
pubmed: 1742381
PLoS Med. 2007 Nov 27;4(11):e336
pubmed: 18044983
Pediatr Infect Dis J. 2008 Jan;27(1):33-7
pubmed: 18162935
Lancet. 1990 Feb 3;335(8684):270-3
pubmed: 1967730
Lancet. 1990 Mar 17;335(8690):641-5
pubmed: 1969023
Lancet Infect Dis. 2011 Jun;11(6):482-7
pubmed: 21616458
Lancet Infect Dis. 2012 Nov;12(11):837-44
pubmed: 22954655
Bull World Health Organ. 2012 Oct 1;90(10):714
pubmed: 23109735
Clin Infect Dis. 2013 Apr;56(8):1123-31
pubmed: 23362293
Int J Epidemiol. 1990 Mar;19(1):187-96
pubmed: 2351514
Vaccine. 2015 Nov 27;33(48):6878-83
pubmed: 26364121
Lancet Infect Dis. 2017 Oct;17(10):1080-1088
pubmed: 28729167
Int J Infect Dis. 2018 Jan;66:90-95
pubmed: 29174695
Int J Epidemiol. 2019 Apr 09;:null
pubmed: 30968110
Int J Epidemiol. 1988 Jun;17(2):456-63
pubmed: 3403141
Nature. 1985 Nov 28-Dec 4;318(6044):323-9
pubmed: 3906406
Am J Epidemiol. 1982 Dec;116(6):959-70
pubmed: 7148820
Am J Epidemiol. 1995 Feb 1;141(3):187-97; discussion 185-6
pubmed: 7840092
Epidemiol Rev. 1993;15(2):265-302
pubmed: 8174658
JAMA. 1996 Oct 9;276(14):1181-5
pubmed: 8827975

Auteurs

Mohammad Ali (M)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

John Clemens (J)

International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.

Classifications MeSH